CASE TX/4-33176A

JC20 Rec'd PCT/PTO 13 OCT 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

FORSTNER ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2004/003982

FILED: 15 APRIL 2004

U.S. APPLICATION NO: Not Yet Known

35 USC §371 DATE: Herewith

FOR: VAV INHIBITION IN GRAFT REJECTION

MS: Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP2004/003982, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

isan Keso

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (862) 778-7859

Date: October 12,2005

Susan Hess

Attorney for Applicants

Reg. No. 37,350

FORM PTO-1449 (REV. 7-85)

AT

EXAMINER

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET 1007552836

TX/4-33176A

APPLICATION NO.

Not Yet Known
ARRUGANT
FORSTNER ET IAL.

1 3 OCT 2005

FILING DATE

Group

Herewith

			U.S. PA	TENT DOCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILI	NG DAT
	AA							
	AB							
	AC							
	AD							
	AE							
	AF							
	AG							
	АН							
	Al							
	AJ							
	AK							
	AL			**				
			FOREIGN	PATENT DOCUMENTS				
		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
	AM			<u> </u>				
	AN							
	AO							
	AP							
	AQ							
		OTHER DOC	JMENTS (Inc	cluding Author, Title, Date, Pe	ertinent pages, E	tc.)		•
	AR	Katzav, "Vav 1: An On Vol. 103, No. 7, pp. 24		Regulates Specific Transc 4).	riptional Activ	ation of T Ce	lls", Blo	ood,
	AS			al Integrators for Multi-Su , No. 7, pp. 476-486 (200		-Recognition	Recep	otors",
	.1	Schuebel et al., "Phos						

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

DATE CONSIDERED

and Oncogenic Vav-2", EMBO, Vol. 17, No. 22, pp. 6608-6621 (1998).

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

JC20 Rec'd PCT/PTO 1 3 OCT 2005

TX/4-33176AAAPPLICATIONING. 552836

APPLICANT
FORSTNER ET AL.
FILING DATE

Herewith

Group

EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)					
	DA	Kaminuma et al., "Vav-Racl-Mediated Activation of the c-Jun N-terminal Kinase/c-Jun/AP-1 Pathway Plays a Major Role in Stimulation of the Distal NFAT Site in the Interleukin-2 Gene Promotor", Molecular and Cellular Biology, Vol. 21, No. 9, pp. 3126-3136 (2001).				
	DB	Germani et al., "hSiah2 is a New Vav Binding Protein Which Inhibits Vav-mediated Signaling Pathways", Molecular and Cellular Biology, Vol. 19, No. 5, pp. 3798-3807 (1999).				
	DC	Abbas, "Cellular and Molecular Immunology", W. B. Saunders, Philadelphia, USA, p. 166 (1997).				
	DD					
	DE					
	DF					
	DG					
	DH					
	DI					
	DJ					
	DK					
	DL					
	DM					
	DN					
EXAMINE	R	DATE CONSIDERED				

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.